1056164-52-3
Chemical Structure
PF-03715455
- CAS. Nr.: 1056164-52-3
- Formula:C35H34ClN7O3S2
- Molecular Weight:700.27
IUPAC Name: 1-(3-(tert-butyl)-1-(3-chloro-4-hydroxyphenyl)-1H-pyrazol-5-yl)-3-(2-((3-(2-((2-hydroxyethyl)thio)phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)thio)benzyl)urea
InChIKey: VGEXRDWWPSGZDH-UHFFFAOYSA-N
SMILES: CC(C)(C1=NN(C2=CC=C(O)C(Cl)=C2)C(NC(NCC3=CC=CC=C3SC4=CN5C(C6=CC=CC=C6SCCO)=NN=C5C=C4)=O)=C1)C
Biological Activity: PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PF-03715455 | 98.44% | PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.52
HY-16782RPexmetinib (Standard) -
Similarity Score 0.50
HY-147518p38-α MAPK-IN-5 -
Similarity Score 0.49
HY-13024ARebastinib tosylate -
Similarity Score 0.49
HY-120595JNJ-49095397 -
Similarity Score 0.48
HY-12847CCT241161 -
Similarity Score 0.48
HY-125387TOP1210 -
Similarity Score 0.48
HY-174427RN341 -
Similarity Score 0.48
HY-14716CCT239065 -
Similarity Score 0.47
HY-12846CCT196969 -
Explore the MedChemAI to find more analogs
References
- [1]. Norman P, et al. Investigational p38 inhibitors for the treatment of chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2015 Mar;24(3):383-92. [Content Brief]
- [2]. Millan DS, et al. Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease. J Med Chem. 2011 Nov 24;54(22):7797-814. [Content Brief]
